Table 3.

Risk of Non-Hodgkin Lymphoma by tertiles of circulating markers and BMI^a

	Body Mass Index (BMI)				pinteraction b
	<25 kg/m2		25 kg/m2
	Cases/controls	OR (95% CI)	Cases/controls	OR (95% CI)
Leptin, ng/ml					<0.0001
<6.4	65/103	1.00	40/62	1.00
6.4–<14.9	31/81	0.52 (0.24, 1.09)	60/102	0.84 (0.45, 1.55)
≥14.9	13/41	0.35 (0.10, 1.18)	63/151	0.54 (0.26, 1.12)
ptrend c		0.02		0.02
IL-10, pg/mL					0.14
<0.64	28/83	1.00	40/114	1.00
0.64–<1.19	33/77	0.82 (0.34, 1.93)	44/117	0.87 (0.47, 1.62)
≥1.59	48/66	1.56 (0.65, 3.71)	79/84	2.46 (1.33, 4.54)
ptrend c		0.40		<0.01

Abbreviations: BMI, body mass index; CI, Confidence interval; CRP, C-reactive protein; IFN, Interferon; IL, Interleukin; OR, odds ratio; TNF, Tumor neurosis factor.

^aOR and 95% CI estimated by conditional logistic regression; cases and controls matched on sex, birthdate (± 1 year), ethnicity (white, Japanese American, Latino, African American, or Native Hawaiian), location (California or Hawaii), date of blood draw (within ±1 year), time of day of blood draw, and fasting hours prior to blood draw (0–<6, 6–<8, 8–<10, or ≥10). Data were missing for leptin (1).

^bp_interaction based on the Wald χ² test of the cross-product terms between log-transformed continuous serum measure and continuous BMI.

^cp_rend based on the Wald χ² test of a log-transformed continuous variable.